Biomarin Pharmaceutical (BMRN) Long-Term Deferred Tax (2016 - 2025)
Historic Long-Term Deferred Tax for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $1.5 billion.
- Biomarin Pharmaceutical's Long-Term Deferred Tax fell 141.56% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 141.56%. This contributed to the annual value of $1.5 billion for FY2024, which is 365.14% down from last year.
- Per Biomarin Pharmaceutical's latest filing, its Long-Term Deferred Tax stood at $1.5 billion for Q3 2025, which was down 141.56% from $1.4 billion recorded in Q2 2025.
- In the past 5 years, Biomarin Pharmaceutical's Long-Term Deferred Tax registered a high of $1.5 billion during Q1 2024, and its lowest value of $1.4 billion during Q2 2025.
- Moreover, its 5-year median value for Long-Term Deferred Tax was $1.5 billion (2024), whereas its average is $1.5 billion.
- Per our database at Business Quant, Biomarin Pharmaceutical's Long-Term Deferred Tax skyrocketed by 16470.6% in 2021 and then tumbled by 763.65% in 2025.
- Quarter analysis of 5 years shows Biomarin Pharmaceutical's Long-Term Deferred Tax stood at $1.5 billion in 2021, then grew by 3.81% to $1.5 billion in 2022, then rose by 2.68% to $1.5 billion in 2023, then decreased by 3.65% to $1.5 billion in 2024, then increased by 1.33% to $1.5 billion in 2025.
- Its Long-Term Deferred Tax was $1.5 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.5 billion in Q1 2025.